[e-farmacos] WHO Pharmaceuticals Newsletter No. 2, 2007

["Canas, Martin" <macanas@netverk.com.ar>]

WHO Pharamceuticals Newsletter No. 2, 2007Estimadas y estimados
 el WHO Pharmaceuticals Newsletter (No. 2, 2007)

cuyo indice es:

Regulatory Matters
Aprotinin -- Label updated for specific use, new safety information...1
Attention deficit hyperactivity disorder (ADHD)-treatments -- Patients to be
notified of cardiovascular and psychiatric events .. 1
Drug-eluting stents -- To be used with utmost restraint ... 1
Interferon-1b -- Not approved for idiopathic pulmonary fibrosis ... 1
Isotretinoin -- Web page about dangers of online buying ... 2
Metoclopramide -- Increasing reports of extrapyramidal symptoms in children;
paediatric use tightened ... 2
Miconazole -- Interaction with warfarin... 2
Omalizumab -- Label update about anaphylaxis... 3
Pentavalent rotavirus (W179-9) vaccine -- Label updated with information on
intussusception and haematochezia ... 3
Pergolide -- Risk of heart valve damage; to be removed from the market... 4
Pioglitazone -- Fractures in females... 4
Sedative-hypnotic drugs -- Stronger warnings about allergic reactions and
sleep-related complex behaviours... 5
Tegaserod -- Withdrawn due to life-threatening cardiac effects... 5
Telithromycin -- Updates on use, contraindications, adverse events ... 5
Topical anaesthetics -- Professional advice needed before use in cosmetic procedures... 6
Safety of Medicines
Angiotensin Converting Enzyme (ACE) inhibitors -- Reports of visual disturbances... 7
Antiepileptic drugs -- Enzyme-inducing drugs may increase fracture risk ... 7
Antipsychotics -- Reports of neuroleptic malignant syndrome ...7
Bupropion -- Reports of depression... 7
Carbasalate -- Reports of tinnitus... 7
Codeine -- Lowest dose recommended in nursing mothers... 8
Deferasirox -- Reports of renal failure ... 8
Domperidone -- Heart rate and rhythm disorders ... 8
Entecavir -- Report of a resistant HIV-variant in HIV/HBV co-infected patient ... 9
Erythropoiesis-stimulating agents -- New studies suggest serious and life threatening side effects ... 9
Estazolam -- Present in a dietary supplement ... 10
Fluticasone -- Reports of behavioural changes ... 10
Goserelin, buserelin -- Reports of psychiatric disorders... 10
Levofloxacin -- Reports of blood glucose, liver and biliary disorders: an
update... 10
Linezolid -- Risk of death when used in catheter-related blood stream
infections ... 11
Olanzapine -- Reports of amenorrhoea ... 11
Oseltamivir -- Close monitoring of treated children and adolescents... 11
Quetiapine -- Reports of alopecia... 12
Selective serotonin reuptake inhibitors (SSSRIs), Venlafaxine -- Reports of
bruxism ... 12
Ranibizumab -- Intravitreal injections and incidence of stroke... 12
Rosiglitazone -- Increased risk of fractures in women receiving long-term
treatment... 12
Tacrolimus -- Reports of malignancies ... 13
Zolpidem -- Reports of sleep walking ... 13
Feature
Recommendations of the fourth meeting of the WHO Advisory Committee on
Safety of Medicinal Products, 26 and 27 February 2007... 14

proximamente estara  disponible en:

http://www.who.int/medicines/publications/newsletter/en/index.html

Saludos,

Martin

Martin Canas
GAPURMED
La Plata
(Argentina)
macanas@netverk.com.ar